Printable Handouts

PDF

Navigable Slide Index

1. Intro slide
2. MND/ALS
3. Amyotrophic Lateral Sclerosis: core facts
4. Pathology of ALS
5. Molecular pathology of sporadic ALS
6. What is the cause of MND?
7. Evidence from genetics
8. Genetic basis of ALS-MND
9. Familial ALS
10. Mutations in SOD1 in familial ALS
11. Superoxide dismutase Type 1
12. FALS due to SOD1 mutations
13. SOD1 activity/disease severity in mouse models
14. Transgenic mouse model
15. SOD1 mutations and oxidative metabolism
16. Natural history in SOD1 mutant mice
17. SOD1 gain of function
18. Protein aggregation
19. Mitochondrial dysfunction
20. Mitochondrial dysfunction 2
21. Excitotoxicity in ALS
22. Neurofilaments
23. Role of inflammation
24. Role of protein aggregation
25. Apoptosis
26. Vascular Endothelial Growth Factor (1)
27. Vascular Endothelial Growth Factor (2)
28. VEGF in human ALS
29. VEGF as a potential therapy
30. Mouse drug studies
31. Positive animal (SOD G93A) trials
32. Human therapeutic trials
33. Mouse models
34. Motor neuron death is a multistep process
35. Lessons from other motor neuron disorders
36. ALS-Parkinsonian Complex of Guam
37. 'ALS2''
38. ALS4''
39. 'ALS8''
40. Other genetic motor neuron disorders
41. RNA metabolism and motor neurone disorders
42. Mechanisms of motor neurone degeneration
43. Future prospects
44. Summary

Topics Covered

• Models of MND pathogenesis
• Current understanding on genetic basis of MND
• Animal and cellular models
• Pathways of motor neurone vulnerability
• Abnormal protein handling
• Mitochondrial dysfunction
• Abnormalities in axonal transport and apoptosis
• Current limitations in treatment
• Role of genetic research in identifying biological basis
• Future directions and developing biomarkers

Links

Series:

• Neurodegenerative Diseases

Categories:

• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 22, 2016

Financial Disclosures

• Prof. Kevin Talbot has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.